TARO-PERAMPANEL DIN 02522659
Health Canada record
| Active ingredient(s) | PERAMPANEL 6 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N03AX22 PERAMPANEL |
| Original market date | 04-Dec-2023 |
| Current status date | 04-Dec-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Taro Pharmaceuticals Inc — licence 100232, not currently licensed, last inspection rating C (2025-03-24).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing PERAMPANEL
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02404524 | FYCOMPA | EISAI LIMITED | Tablet | PERAMPANEL 4.0 MG | Marketed |
| 02404532 | FYCOMPA | EISAI LIMITED | Tablet | PERAMPANEL 6.0 MG | Marketed |
| 02404540 | FYCOMPA | EISAI LIMITED | Tablet | PERAMPANEL 8.0 MG | Marketed |
| 02404559 | FYCOMPA | EISAI LIMITED | Tablet | PERAMPANEL 10.0 MG | Marketed |
| 02404567 | FYCOMPA | EISAI LIMITED | Tablet | PERAMPANEL 12.0 MG | Marketed |
| 02404516 | FYCOMPA | EISAI LIMITED | Tablet | PERAMPANEL 2 MG | Marketed |
| 02522683 | TARO-PERAMPANEL | TARO PHARMACEUTICALS INC | Tablet | PERAMPANEL 12 MG | Marketed |
| 02522667 | TARO-PERAMPANEL | TARO PHARMACEUTICALS INC | Tablet | PERAMPANEL 8 MG | Marketed |
| 02522632 | TARO-PERAMPANEL | TARO PHARMACEUTICALS INC | Tablet | PERAMPANEL 2 MG | Marketed |
| 02522640 | TARO-PERAMPANEL | TARO PHARMACEUTICALS INC | Tablet | PERAMPANEL 4 MG | Marketed |
| 02522675 | TARO-PERAMPANEL | TARO PHARMACEUTICALS INC | Tablet | PERAMPANEL 10 MG | Marketed |
| 02460106 | FYCOMPA | EISAI LIMITED | Suspension | PERAMPANEL 0.5 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 32213 | 2023-11-30 | Abbreviated New Drug Submission (ANDS) |
International API supply for PERAMPANEL
10 active FDA Drug Master Files.
Request a quote for TARO-PERAMPANEL